Show simple item record

dc.contributor.authorForsse, David Eriken_US
dc.contributor.authorTangen, Ingvild Løbergen_US
dc.contributor.authorFasmer, Kristine Eldeviken_US
dc.contributor.authorHalle, Mari Kyllesøen_US
dc.contributor.authorViste, Kristinen_US
dc.contributor.authorAlmås, Bjørgen_US
dc.contributor.authorBertelsen, Bjørn-Eriken_US
dc.contributor.authorTrovik, Joneen_US
dc.contributor.authorHaldorsen, Ingfrid S.en_US
dc.contributor.authorKrakstad, Camillaen_US
dc.date.accessioned2020-05-22T17:26:10Z
dc.date.available2020-05-22T17:26:10Z
dc.date.issued2020-02
dc.PublishedForsse De, Tangen IL, Fasmer KE, Halle MK, Viste K, Almås B, Bertelsen, Trovik J, Haldorsen IS, Krakstad C. Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 2019:156(2)eng
dc.identifier.issn1095-6859
dc.identifier.issn0090-8258
dc.identifier.urihttps://hdl.handle.net/1956/22358
dc.description.abstractObjective Blood-based biomarkers are attractive due to ease of sampling and standardized measurement technology, reducing obstacles to clinical implementation. The objective of this study was to evaluate a clinically available method of steroid hormone measurement for its prognostic potential in endometrial cancer. Methods We quantified seven steroid hormones by liquid chromatography-tandem mass spectrometry in 100 endometrial cancer patients from a prospective cohort. Abdominal fat distribution was assessed from abdominal computed tomography (CT) scans. Steroid hormone levels were compared to clinical characteristics, fat distribution and gene expression in primary tumor samples. Results Low levels of 17OH-progesterone, 11-deoxycortisol and androstenedione were associated with aggressive tumor characteristics and poor disease specific survival (p = .003, p = .001 and p = .02 respectively). Adjusting for preoperative risk based on histological type and grade, low 17OH-progesterone and 11-deoxycortisol independently predicted poor outcome with hazard ratios of 2.69 (p = .033, 95%CI: 1.09–6.68) and 3.40 (p = .020, 1.21–9.51), respectively. Tumors from patients with low steroid level displayed increased expression of genes related to mitosis and cell cycle progression, whereas high steroid level was associated with upregulated estrogen signaling and genes associated with inflammation. Estrone and estradiol correlated to abdominal fat volume in all compartments (total, visceral, subcutaneous, p < .001 for all), but not to the visceral fat proportion. Patients with higher levels of circulating estrogens had increased expression of estrogen signaling related genes. Conclusion Low levels of certain endogenous steroids are associated with aggressive tumor traits and poor survival and may provide preoperative information independent of histological biomarkers already in use.en_US
dc.language.isoengeng
dc.publisherElseviereng
dc.rightsAttribution CC BYeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subjectEndometrial cancereng
dc.subjectSteroid hormoneseng
dc.subjectSurvivaleng
dc.subjectEstrogen signalingeng
dc.subjectCirculating biomarkerseng
dc.subjectFat distributioneng
dc.titleBlood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signalingen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2020-01-23T12:30:20Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2019 The Author(s)
dc.identifier.doihttps://doi.org/10.1016/j.ygyno.2019.11.123
dc.identifier.cristin1780852
dc.source.journalGynecologic Oncology
dc.relation.projectKreftforeningen: 190202
dc.relation.projectHelse Vest RHF: HV 440088
dc.relation.projectNorges forskningsråd: 273280
dc.identifier.citationGynecologic Oncology. 2020, 156 (2), 400-406.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY